Recent research of pooled bispecific antibody clinical trial data shows that infections can be common and that more study needs to be performed to know how to best reduce infection rates for patients.
The authors start a recent article in the journal Blood Advances with a bang:
“The use of bispecific antibodies (BsAbs) in the treatment of relapsed/refractory multiple myeloma (MM) is showing early promising overall response rates in heavily pre-treated patients. Infectious complications related to the use of BsAbs are not well described.”
This research article summarizes a pooled analysis of 11 published clinical studies with 11 different bispecific antibodies, covering 1,185 myeloma patients, where bispecific antibodies were administered as a single agent to patients with no prior exposure to another bispecific antibody.
Let’s pause for a minute and re-hash some education about bi-specifics. Bispecific antibodies bind to a target on the cancerous myeloma (plasma) cells as well as on immune effector cells resulting in cell death of the malignant cell. Bispecific antibodies used in myeloma can target BCMA (and those are the ones we are most familiar with from the more popular myeloma press] or the protein GPRC5D or FcRH5.)
The products included in this study can be categorized as follows:
The authors report the following:
The question to ask is, “Why ?” The authors list 3 main reasons:
The authors make several points and recommendations:
Those patients currently being treated with bispecific antibodies may wish to discuss some of these recommendations with their myeloma specialist, especially point 6 above.
about the author
Paul Kleutghen
I am a patient diagnosed in 2014 with primary plasma cell leukemia (pPCL), a rare and aggressive variant of multiple myeloma and have been very fortunate to find successful treatment at the division of Cellular Therapy at the Duke University Cancer Institute. My wife, Vicki, and I have two adult children and two grandsons who are the ‘lights of our lives’. Successful treatment has allowed Vicki and I to do what we love best : traveling the world, albeit it with some extra precautions to keep infections away. My career in the pharmaceutical industry has given me insights that I am currently putting to use as an advocate to lower drug pricing, especially prices for anti-cancer drugs. I am a firm believer that staying mentally active, physically fit, compliant to our treatment regimen and taking an active interest in our disease are keys to successful treatment outcomes.
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.